drugset / Trial / NCT06968338
A Study to Assess the Safety of ARGX-213 in Healthy Volunteers
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study aims to assess the safety of ARGX-213 in healthy adults. Another aim is to measure the amount of ARGX-213 in the blood over time to learn how it moves through the body and acts in the body. The participants will remain in the study for approximately up to 21 weeks.
Timeline
- Start
- 2025-04-11
- Primary completion
- 2026-03-20
- Completion
- 2026-03-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARGX-213 | Unknown | — | Intravenous |
Indications
No indication recorded.